Undifferentiated Ovarian Carcinoma Completed Phase 1 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0028876 (Undifferentiated Ovarian Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01459380Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerTreatment
NCT01489371EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTreatment
NCT01294293TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerTreatment